Author | Year | Study Type | Substance | Control | Mean VAS | Mean no of injections | Serious Adverse Events | ||
---|---|---|---|---|---|---|---|---|---|
pre | post | FU | |||||||
Sclerotherapy | |||||||||
Alfredson | 2004 | prospective | polidocanol 5 mg/ml | na | 79.7 | 19 | 2.7 | none | |
Gisslén | 2006 | casereport | polidocanol 10 mg/ml | na | 90 | 0 | 0 | 1.0 | none |
Hoksrud | 2006 | RCT | polidocanol 10 mg/ml | adrenaline 5 μg/ml+lidocaine hcl 5 mg/ml | VISA | VISA | VISA | 3.1 (intervention + crossover) | none |
Willberg | 2011 | RCT | polidocanol 10 mg/ml | arthroscopic shaving | 69 | 41.1 | (17) | na | none |
Hoksrud | 2012 | prospective | polidocanol 10 mg/ml | na | VISA | VISA | VISA | 2.5 | none |
Prolotherapy | |||||||||
Ryan | 2011 | prospective | 25% dextrose solution | na | 51.1 | 25.8 | median 4 | none | |
Topol | 2011 | RCT | 12.5% dextrose solution | lidocaine 10 mg/ml | NPPS | NPPS | NPPS | 3.8 | none |